drugset
drugset / Trial / NCT07134478

Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects

NCT07134478 ↗

Phase 1 Active not recruiting 24 enrolled Haisco Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, open-label, two-period, fixed-sequence clinical study to evaluate the effect of Rifampicin on the pharmacokinetics of HSK31858 in healthy subjects

Timeline

Start
2024-10-28
Primary completion
2024-12-24
Completion
2026-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK31858 Unknown 40 mg —
Subject Rifampicin Small molecule 600 mg —

Indications

No indication recorded.